文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

免疫性血栓性血小板减少性紫癜:综述

Immune Thrombotic Thrombocytopenic Purpura: A Review.
PubMed 文献 · JAMA · 2025-01-01
一句话结论对MAHA伴血小板减少者,ADAMTS13结果未回前可依据预测评分(血小板<30×10⁹/L且肌酐<2.0 mg/dL)启动血浆置换、糖皮质激素和利妥昔单抗,可使30天生存率超过90%。

本综述总结免疫性血栓性血小板减少性紫癜(iTTP)由ADAMTS13自身抗体导致ADAMTS13活性严重降低(<10%),引起微血管病性溶血性贫血和血小板减少,全球年发病率2–6例/百万人。常见表现为神经系统症状(39%–80%)和腹痛(35%–39%)。治疗性血浆置换联合糖皮质激素和利妥昔单抗可将生存率从几乎为零提高至约93%。加用caplacizumab可缩短血小板计数正常化时间并减少治疗结束后30天内早期复发(风险差-29%),但出血风险增加(风险差17%)。缓解期ADAMTS13活性<20%时给予利妥昔单抗可降低复发风险(OR 0.09)。

要点

  • 对MAHA伴血小板减少者,ADAMTS13结果未回前,若血小板<30×10⁹/L且肌酐<2.0 mg/dL(176.8 μmol/L),可用临床预测评分指导经验性启动iTTP治疗。
  • 治疗性血浆置换、糖皮质激素和利妥昔单抗联合可使iTTP生存率从几乎为零提高至约93%。
  • caplacizumab与免疫抑制及治疗性血浆置换同时使用并持续至ADAMTS13恢复,可缩短血小板计数正常化时间,并减少治疗性血浆置换结束后30天内早期复发(风险差-29%,95%CI -42%至-14%),但出血风险增加(风险差17%,95%CI 4%–30%)。
  • 达到临床缓解(至少30天血小板计数持续正常、血清乳酸脱氢酶下降且无新发或进展性缺血性器官损伤,且未接受治疗性血浆置换或caplacizumab)后,16%的患者至少复发1次。
  • 缓解期定期监测ADAMTS13活性,对ADAMTS13活性<20%者给予利妥昔单抗可降低复发风险(OR 0.09,95%CI 0.04–0.24)。

适用人群与场景

  • 成人iTTP发病率高于儿童(发病率比31.62/百万人年,95%CI 14.68–68.10);女性高于男性(发病率比3.19,95%CI 2.65–3.85);黑人高于非黑人(发病率比7.09,95%CI 6.05–8.31)。
  • 表现为微血管病性溶血性贫血(MAHA)和血小板减少的患者。

诊断标准与关键阈值

  • ADAMTS13活性严重降低(<10%)支持iTTP诊断。
  • 临床预测评分可基于实验室数据(如血小板计数<30×10⁹/L和肌酐<2.0 mg/dL〔176.8 μmol/L〕)在ADAMTS13结果未回前指导经验性治疗启动。
  • 临床缓解定义为至少30天血小板计数持续正常、血清乳酸脱氢酶水平下降且无新发或进展性缺血性器官损伤,未接受治疗性血浆置换或caplacizumab。
  • 缓解期ADAMTS13活性<20%为复发高危阈值,此时给予利妥昔单抗。

处置流程与药物剂量

  • 对MAHA伴血小板减少者,在ADAMTS13结果未回前,可依据临床预测评分(如血小板<30×10⁹/L且肌酐<2.0 mg/dL)经验性启动iTTP治疗。
  • 及时启动治疗性血浆交换、糖皮质激素和利妥昔单抗。
  • caplacizumab与免疫抑制及治疗性血浆置换同时给药,并持续至ADAMTS13恢复。
  • 缓解期定期监测ADAMTS13活性,对ADAMTS13活性<20%者给予利妥昔单抗。

红旗征与不能漏的情况

  • 神经系统症状(如头痛、意识模糊或癫痫发作)见于39%–80%的患者。
  • 腹痛见于35%–39%的患者。
  • 微血管血栓可导致缺血性器官损伤(如心肌梗死和卒中)。

研究设计与关键结果

  • 本综述汇总iTTP的发病机制、临床预测评分、治疗及缓解期监测证据。
  • 治疗性血浆置换、糖皮质激素和利妥昔单抗联合使iTTP生存率从几乎为零提高至约93%。
  • caplacizumab与安慰剂相比,缩短血小板计数正常化时间,减少早期复发(治疗性血浆置换结束后30天内)风险差-29%(95%CI -42%至-14%),但出血风险差17%(95%CI 4%–30%)。
  • 临床缓解后16%的患者至少复发1次;缓解期ADAMTS13活性<20%时给予利妥昔单抗降低复发风险(OR 0.09,95%CI 0.04–0.24)。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对MAHA伴血小板减少者,在ADAMTS13结果未回前可依据临床预测评分(如血小板<30×10⁹/L且肌酐<2.0 mg/dL)经验性启动治疗性血浆置换、糖皮质激素和利妥昔单抗。
  • 使用caplacizumab时需权衡其减少早期复发与增加出血风险(风险差17%)的利弊。
  • 缓解期应定期监测ADAMTS13活性,对ADAMTS13活性<20%者给予利妥昔单抗以降低复发风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy that presents with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia. Worldwide annual incidence of iTTP is 2 cases per million to 6 cases per million.

OBSERVATIONS: Immune TTP is caused by an autoantibody to a disintegrin and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13), an enzyme that cleaves von Willebrand factor (vWF). With severely low ADAMTS13 activity (<10%), large multimers of vWF accumulate and bind platelets, forming microvasculature thromboses that cause ischemic organ injury (eg, myocardial infarction and stroke). The incidence of iTTP is higher in adults than children (incident rate ratio [IRR], 31.62 per million person-years [95% CI, 14.68-68.10]), females than males (IRR, 3.19 [95% CI, 2.65-3.85]), and Black compared with non-Black individuals (IRR, 7.09 [95% CI, 6.05-8.31]). Common presenting symptoms are neurologic (eg, headache, confusion, or seizures [39%-80%]) and abdominal pain (35%-39%). For patients presenting with MAHA and thrombocytopenia, clinical prediction scores for iTTP using laboratory data, such as platelet count less than 30 × 109/L and creatinine level less than 2.0 mg/dL (176.8 μmol/L), can help guide empirical treatment initiation for iTTP before ADAMTS13 results are available. Prompt initiation of therapy with therapeutic plasma exchange, corticosteroids, and rituximab improves survival with iTTP from almost zero to approximately 93%. Caplacizumab, a synthetic small antibody (nanobody) that blocks platelet binding to vWF, administered concurrently with immunosuppression and therapeutic plasma exchange and continued until ADAMTS13 recovery, reduces the time to normalization of platelet count and decreases the risk of early recurrence (defined as within 30 days of completing therapeutic plasma exchange) compared with placebo (risk difference [RD], -29% [95% CI, -42 to -14%]) but increases bleeding risk (RD, 17% [95% CI, 4%-30%]). After obtaining clinical remission (defined as at least 30 days of sustained normalization of platelet count, decreased serum lactate dehydrogenase level, and absence of new or progressive ischemic organ injury without therapeutic plasma exchange or caplacizumab), 16% of patients have at least 1 relapse of iTTP. Regular monitoring of ADAMTS13 activity in remission and administration of rituximab when ADAMTS13 activity is less than 20% reduces risk of relapse (odds ratio, 0.09 [95% CI, 0.04-0.24]).

CONCLUSIONS AND RELEVANCE: Immune TTP is a rare immune-mediated disorder that presents with thrombocytopenia and MAHA and may cause life-threatening thrombosis. Treatment with therapeutic plasma exchange, corticosteroids, and rituximab is associated with 30-day survival rates of more than 90%. Addition of caplacizumab shortens time to normalization of platelet count and reduces recurrences while receiving the drug but increases bleeding risk. Monitoring ADAMTS13 activity in survivors and initiation of rituximab for those with low ADAMTS13 activity reduces the risk of clinical relapse.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pishko AM, Li A, Cuker A, et al. Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025. PMID: 40388146. doi:10.1001/jama.2025.3807

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。